Zoetis (ZTS)
(Delayed Data from NYSE)
$159.70 USD
+1.28 (0.81%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $159.76 +0.06 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.70 USD
+1.28 (0.81%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $159.76 +0.06 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
The Zacks Analyst Blog Highlights Invitation Homes, Choice Hotels International, Zoetis and Owens Corning
by Zacks Equity Research
Invitation Homes, Choice Hotels International, Zoetis and Owens Corning are part of the Zacks top Analyst Blog.
4 Stocks to Watch That Recently Declared Dividend Hikes
by Ritujay Ghosh
Invitation Homes Inc. (INVH), Choice Hotels International, Inc. (CHH), Zoetis Inc. (ZTS) and Owens Corning (OC) recently announced dividend hikes.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Here's What Key Metrics Tell Us About Zoetis (ZTS) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zoetis' (ZTS) Q3 Earnings Beat, Revenues Miss by a Whisker
by Zacks Equity Research
Zoetis' (ZTS) third-quarter 2023 earnings surpass estimates. However, revenues fall marginally short. The strong performance of the companion animal portfolio drives year-over-year revenues.
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Research Reports for Costco, Pfizer & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp. (COST), Pfizer Inc. (PFE) and IBM Corp. (IBM).
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in the third quarter of 2023, partially offset by declining swine product sales.
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Zacks Analyst Blog Highlights The Procter & Gamble, The Home Depot, Danaher, Zoetis and Itau Unibanco Holding
by Zacks Equity Research
The Procter & Gamble, The Home Depot, Danaher, Zoetis and Itau Unibanco Holding are part of the Zacks top Analyst Blog.
Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Top Research Reports for Procter & Gamble, Home Depot, Danaher & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), The Home Depot, Inc. (HD) and Danaher Corporation (DHR).